Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$105.4MBeat by $1.7M
EPS-$0.09Miss by $0.07
Revenue estimate$103.7M
EPS estimate-$0.02

Next report

Oct 27, 2026 (in a month)
Revenue estimate$141.7M
EPS estimate$0.17

Financials

Q1 2026

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.92B+57.5%
Enterprise value$3B+57.0%
P/S7×-1.7×

Profitability

See full
Gross margin90.9%+2.5pp

Returns & leverage

See full
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Segments

By segment

See full
Reportable Segment$105.4M+60.1%

FAQ

When did Arcutis Biotherapeutics, Inc. report Q1 2026 earnings?
Arcutis Biotherapeutics, Inc. (ARQT) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Arcutis Biotherapeutics, Inc.'s Q1 2026 revenue and EPS?
Arcutis Biotherapeutics, Inc. reported revenue of $105.4M and eps of $-0.09 for Q1 2026.
Did Arcutis Biotherapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $103.7M by $1.7M. EPS missed the consensus estimate of $-0.02 by $0.07.
How did Arcutis Biotherapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 60.1% from $65.8M a year earlier and eps grew 55.0% from $-0.20.
Where can I find Arcutis Biotherapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001787306-26-000039) and the 10-Q periodic report (0001787306-26-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.